Sutro Biopharma (STRO) Expected to Announce Earnings on Monday

Sutro Biopharma (NASDAQ:STRO) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The company had revenue of $14.00 million for the quarter, compared to analysts’ expectations of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same quarter in the prior year, the business posted ($1.78) earnings per share. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $0.77 on Friday. The business has a 50 day simple moving average of $1.64 and a 200-day simple moving average of $2.62. The stock has a market capitalization of $63.24 million, a PE ratio of -0.48 and a beta of 1.22. Sutro Biopharma has a 12 month low of $0.76 and a 12 month high of $6.13.

Analyst Ratings Changes

STRO has been the topic of a number of recent research reports. Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research note on Friday, March 14th. Citizens Jmp cut Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. Piper Sandler set a $2.00 target price on Sutro Biopharma in a research report on Friday, March 14th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective (down from $12.00) on shares of Sutro Biopharma in a research report on Monday, March 17th. Finally, Bank of America cut Sutro Biopharma from a “buy” rating to an “underperform” rating and reduced their price target for the company from $11.00 to $1.00 in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.63.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.